News About: Pharm. Industry
It is analyzed that domestic pharmaceutical industry will be organized again with top pharmaceutical companies as center
Kiwoom Securities analyzed through the "Business outlook for the second half of 2014" report, that domestic pharmaceutical industry will be organized again with top pharmaceutical companies as center.
First, as targe...
SG & A expenses of Japanese pharmaceutical companies in Korea were higher than those of domestic pharmaceutical companies
According to the SG & A expenses of 7 Japanese pharmaceutical companies which entered into domestic market in last year, SG & A expenses were higher than those of domestic pharmaceutical companies.
The average SG & A...
Chief Executive Officer Teva-Handok, Hong Yoo-Suk move attitude on this July
On July 16, the first Chief Executive Officer of the business venture established between Teva Pharmaceutical Industries Ltd. and Handok Pharmaceuticals Teva-Handok, Hong Yoo-Suk move attitude on this month (July). It...
It was pointed out that the position of small pharmaceutical companies will be reduced in accordance with the implementation of Illegal kickback two-out system
It was pointed out that the position of small pharmaceutical companies will be reduced in accordance with the implementation of Illegal kickback two-out system enforced in July.
Sales reduction of small and medium-si...
Only 2 products received generic drug approval of Nexium
The patent of Nexium (S-omeprazole magnesium • AZ) expires on July 22. However, despite the expiration of patent ahead, only 2 products received generic drug approval.
First reason is because of follow-up patent of N...
Traditional sales approach which depends on the complexity of distribution channels is exposing its limit
Sales of generic drugs (patent expired) are expected to slow down due to government's regulation policy on illegal kickback such as Illegal kickback two-out system followed by dual punishment.
In response, the indust...
As the fourth medicine for Risk-sharing, 'Xtandi soft capsule (enzalutamide)' is likely to be selected
As the fourth medicine for Risk-sharing, Astellas Pharmaceutical's prostate cancer treatment 'Xtandi soft capsule (enzalutamide)' is likely to be selected.
On July 10, it was known that Health Insurance Review and As...
Health Insurance Review and Assessment Service apply insurance coverage of six chemotherapies which exceeded approval range
On July 14, Health Insurance Review and Assessment Service preannounce revision of 'A detail about application standard and measure of Medical Care Benefit regarding drugs prescribed to cancer patients' for applying i...
Ministry of Food and Drug Safety ordered to stop using drug substance imported from Italia, according to the Rapid Alert from PIC/S
On July 11, Ministry of Food and Drug Safety announced that they ordered to stop using drug substance 'Clonidine hydrochloride' and some products of 'Tetrahydrozoline' which were imported from Italian Pharmaceutical c...
Some are voicing an opinion which point out that domestic patient’s accessibility of medicine is getting weakened
As assessment that new drugs do not received proper price in domestic expands, some are voicing an opinion which points out that so called 'Access to Medicine' is getting weakened. In particular, they concern that it ...
